Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25522892 | 0.82 | MAPT (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18665157 | 0.78 | ALDH1A1 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22645938 | 0.77 | CYP1A2 (0.38) | CYP2C9CYP2C19 | |
| SCHEMBL21473465 | 0.77 | — | — | |
| SCHEMBL22339524 | 0.77 | AOC3 (0.31) | — | |
| SCHEMBL23783536 | 0.74 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24937886 | 0.73 | HDAC1 (0.33) | — | |
| SCHEMBL21472310 | 0.73 | HDAC1 (0.33) | — | |
| SCHEMBL31421539 | 0.72 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21231246 | 0.72 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| WO-2021178841-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | JANPIX, LTD. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178841-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | JANPIX, LTD. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | GRIN2D 4608/4885GRIN3B 4120/4885GRIN1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.